PHGE Company Profile and Key Details

PHGE has shown mixed momentum, gaining 22.22% over the past week and -75.43% over the past quarter, though year-to-date performance is up 47.06%. Short-term trend indicators are mixed aligned (SMA20 -14.89%, SMA50 22.14%, SMA200 -39.1%). The stock’s 14-day RSI is 47.74 (neutral), while the ATR of 0.85 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.54% below its high and over 204.59% above its low. Average 10-day trading volume of 7.46 million shares is in line with the 3-month average of 7.15 million, indicating normal recent market interest.

BiomX Inc. has 26.55 million shares outstanding. The public float is 18.01 million shares, elevated short interest at 1.91% of float. This equals 501.42 thousand shares. The short ratio is 0.05 days. Institutional investors hold 5.51% of the float. Insiders own 31.77%. OrbiMed Israel BioFund GP Limited Partnership holds 13.77 million shares, Ugwumba Chidozie has 3.00 million shares and Chimovits Erez has 2.31 million shares. Over the past six months, insider transactions show net selling. They sold 2.60 million shares across 3 transactions.

BiomX Inc. generated EPS of -$23.88 over the past year. Five-year average earnings growth is 38.28%. Wall Street analysts project EPS growth of 41.2% annually over the next five years. The latest quarter delivered EPS of -$4.61. The next quarter is forecast at -$5.06. Next year's EPS is expected at $17.71. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $15.00. The high target offers 9185.71% upside. The low target suggests 5257.14% downside. The mean target is $22.33. This offers 7875.0% upside. BiomX Inc. earnings surprise history is a mixed track record. The quarter that ended March 24, 2026, missed forecasts by 0.0%. The prior quarter beat by -100.0%. Over the last six quarters, Apple has recorded several small beats. These include 61.67% in November 14, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

BiomX Inc. (AMEX:PHGE) closed at $0.24 USD, losing -$0.04 (-16.04%) from the previous close of $0.28. The stock is currently mid-range between its 52-week high and low $0.21 and $14.71. With a market capitalization of about $374.65 thousand, BiomX Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 9.15 million shares, in line with its 52-week average. Headquartered in Dover, DE, BiomX Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marina Wolfson, the company employs approximately 20 people and listed since March 13, 2019. Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure.

BiomX Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.81 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.02, also above market averages.

BiomX Inc. (AMEX:PHGE) shares are up 47.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BiomX Inc. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.00, suggesting 4542.86% upside. Our AI forecast model points to short-term weakness (-71.43% over two weeks), a medium-term fall (-92.86% over three months), and a longer-term gain (157.14% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that BiomX Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -71.43%, with price expected at $0.08 by July 23, 2026, within a range of $0.00 to $0.43 3-Month Outlook: Projected fall of -92.86%, reaching $0.02 by October 07, 2026, with a range of $0.00 to $0.45. 1-Year Outlook: Projected gain of 157.14%, with price at $0.72 by July 09, 2027, within a range of $0.00 to $4.65.